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Short Communication
Soft-tissue injury caused by antineoplastic drugs is inhibited
by topical dimethyl sulphoxide and alpha tocopherol
P. Nobbs & R.D. Barr
Department ofPediatrics, McMaster University, Hamilton, Ontario, Canada.
Necrosis of the skin and subcutaneous tissues,
following inadvertent extravasation of cytotoxic
drugs, is a serious and potentially fatal
complication of cancer chemotherapy (Lippman et
al., 1972). Although, in experienced hands, such
extravasation occurs with less than one i.v. injection
in a hundred, more than 5% of patients at risk will
suffer a drug-induced soft-tissue injury since each
receives multiple injections during a conventional
treatment regimen (Barlock et al., 1979).
Having established a model of soft-tissue injury
induced by anti-neoplastic drugs in the guinea pig
(Barr et al., 1981), a preliminary evaluation was
undertaken to assess the prospect of secondary
prophylaxis, i.e. the prevention of gross tissue
damage by pharmacological intervention after the
injurious event. Four agents were selected for study
on the basis of putative or anecdotal value (Barr &
Sertic, 1981). No major benefit was derived from
this approach, at least as it was employed; but
modest diminution in toxicity did follow the use of
hydrocortisone. Indeed, aggressive steroid
intervention may be helpful. in clinical practice
(Barlock et al., 1979), although much more effective
methods ofprevention must be sought.
Following a description of promising results with
the use of topical dimethylsulphoxide (DMSO),
applied either locally or at a site distant from that
harbouring the injurious drug (Desai et al., 1981), a
detailed report of the value of DMSO, alone and
in combination with the anti-oxidant alpha-
tocopherol (Vitamin E), was published very recently
(Svingen et al., 1982). In that study, a mixture of
DMSO and Vitamin E was moderately efficacious
in reducing soft-tissue necrosis induced in rats by
the i.d. injection of Adriamycin. Again, a systemic
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effect of DMSO was suggested. However, in no
instance was the injury prevented completely.
The present study was undertaken to examine the
roles of DMSO and Vitamin E in the secondary
prevention of soft tissue injury following the i.d.
and s.c. injection of Adriamycin in Hartley guinea
pigs which were obtained from Camm Research
Institute Inc., Wayne, New Jersey and
accommodated in groups of 3 or 4 per cage,
receiving Purina Guinea Pig Chow and water ad
libitum. Individual animals were identified by
appropriate ear notches. The skin of the back was
shaved and used as the target site. Shaving was
repeated at intervals of one week.
Adriamycin (Adria Laboratories, Mississauga,
Ontario) was injected s.c. in one ml volumes via
23gauge needles using a single syringe. Intradermal
injections of 0.2ml were accomplished with 25
gauge needles.
DMSO (Fisher Scientific Company, Fair Lawn,
New Jersey) and alpha tocopherol succinate (Sigma
Chemical Company, St. Louis, Missouri) were
employed as intervention agents. The latter was
dissolved in the former (DMSO) to achieve
solutions of 10 and 50g per 100ml. Isotonic saline
was used as the control. One ml volumes of these
solutions were applied topically to the skin with
cotton-tipped applicators immediately after the
injection ofAdriamycin.
Each animal was examined every day and any
lesions observed were scored according to a simple
rating described previously (Barr et al., 1981; Barr
& Sertic, 1981) and given in detail in Table I. At
Table I Intensity of soft tissue injury
Gross appearance Grade Score
Normal - 0
Hyperaemia + 1
Demarcation + + 2
Discolouration + + + 3
Ulceration + + + + 4
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the end of the study period the animals were killed
by i.p. injection of pentobarbital sodium. Two
separate studies were conducted. Replicates of 8
animals were used for each datum point. Statistical
evaluation was performed by analyses of variance.
Study 1 Each guinea pig was injected with 4 doses
of Adriamycin.
A. 2 mg s.c. at left shoulder.
B. 0.005 mg i.d. at right shoulder.
C. 0.01 mg i.d. at right hip.
D. 0.05 mg i.d. at left hip.
Eight animals received topical saline at each
injection site (Group 1); 8 were given DMSO at
each shoulder and saline at each hip (Group 2); and
8 were treated with saline at each shoulder and
DMSO at each hip (Group 3).
All animals in Groups 1 and 3 developed lesions
at site A within 96h with no significant difference
in intensity. From this observation it may be
deduced that neither the application of saline to the
injection site nor the topical administration of
DMSO to a distant site was effective in preventing
tissue damage. However, only 3 animals in group 2
developed lesions at site A. Two of these progressed
to 3 + intensity and may have been due to partial
administration of Adriamycin i.d. inadvertently,
since a double syringe technique (as used in clinical
practice for i.v. injections) was not employed. The
3rd animal developed a lesion at site A on the 4th
day. It attained + maximal intensity and was
healed by Day 7. Accordingly, direct topical
application of DMSO to the site of s.c. injection of
2mg of Adriamycin prevented the appearance of
even minimal tissue damage in the majority of
animals.
Injection of 0.005mg of Adriamycin i.d. evoked
no lesions within 7 days. A dose of 0.01 mg i.d.
produced + lesions in all animals in groups 1 and
2 by one week. Only 50% (4/8) of the animals in
Group 3 had such lesions persisting at one week.
All animals receiving 0.05mg of the drug i.d. had
2+ lesions, there being no apparent benefit from
the topical application of DMSO within the
observation period of 7 days. Thus the ability of
DMSO to modify the tissue damage consequent
upon i.d. injection of Adriamycin is critically
related to the dose of the latter agent.
Study 2 Each guinea pig was injected with 4 doses
of Adriamycin i.d.
A. 0.1 mg at left shoulder.
B. 0.05 mg at left hip.
C. 0.01 mg at right hip.
D. 0.005mg at right shoulder.
Intervention was accomplished by 3 protocols.
1. Eight animals received DMSO alone at each
injection site.
2. Eight animals received DMSO with 10% alpha
tocopherol succinate at each injection site.
3. Eight animals received DMSO with 50% alpha
tocopherol succinate at each injection site.
The mean scores for the lesions at intervals of 3
days are given in Table II and the statistical
analysis is summarized in Table III.
Table II Mean scores of tissue damage at intervals of 3 days
after i.d. injection of Adriamycin and subsequent topical
application of DMSO alone or DMSO with 10 or 50% alpha
tocopherol succinate
Days after injection
Dose Protocol 3 6 9 12 15 18 21
1 2.125 3.000 4 4 4 4 4
A 2 1.750 2.875 4 4 4 4 4
3 1.250 2.625 4 4 4 4 4
1 1.875 2.375 4 4 4 4 4
B 2 1.375 2.125 4 4 4 3.625 3.375
3 0.875 1.375 4 4 4 3.000 3.125
1 1.000 1.250 2.125 2.875 1.625 0.625 0
C 2 0.125 0.625 1.500 2.125 1.375 0 0
3 0 0.125 1.375 2.000 1.375 0 0
1 0 0 0.750 0.875 0.500 0 0
D 2 0 0 0.500 0.250 0.250 0 0
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Table III Levels of significance (P values) in differences between effects of
intervention with DMSO or DMSO with 10 or 50% alpha tocopherol succinate
for secondary prophylaxis of soft-tissue injury induced by i.d. injection of
Adriamycin. NS=Not significant
Days after injection
Protocol
Dose comparison 3 6 9 12 15 18 21
1 vs 2 NS NS NS NS NS NS NS
A I vs 3 NS NS NS NS NS NS NS
2 vs 3 NS NS NS NS NS NS NS
I vs2 <0.05 NS NS NS NS NS <0.05
B 1vs3 <0.005 <0.005 NS NS NS <0.01 <0.05
2vs3 NS <0.005 NS NS NS NS NS
I vs2 <0.001 <0.05 <0.05 NS NS NS NS
C I vs3 <0.001 <0.001 <0.025 <0.025 NS NS NS
2vs3 NS <0.05 NS NS NS NS NS
I vs2 NS NS NS <0.025 NS NS NS
D l vs3 NS NS <0.025 <0.005 <0.05 NS NS
2vs3 NS NS NS NS NS NS NS
Although lesions induced by all doses of
Adriamycin evolved more slowly with the topical
application of increasing concentrations of alpha
tocopherol succinate in DMSO (zero, 10 and 50%
in protocols 1, 2 and 3 respectively), lesions with
doses A and B were fully developed (4+) in all
animals by Day 9. The maximum intensity of soft
tissue injury caused by dose C was delayed to Day
12 and it was inversely related to the concentration
of alpha tocopherol succinate. A similar, albeit less
pronounced effect was seen after dose D, although
no lesion was observed in any animal receiving this
dose within one week of injection. Lesions
following doses C and D resolved completely in all
animals and the rate was related directly to the
concentration of alpha tocopherol succinate used
for intervention. Within 3 weeks the lesions
produced by dose B showed early healing only in
those animals in which intervention by protocols 2
and 3 was undertaken. By 6 weeks all lesions
revealed evidence of healing, although many which
had been 4+ in intensity exhibited prominent scar
formation.
Following inadvertent extravasation in clinical
practice, Adriamycin can be detected in the skin for
several months (Garnick et al., 1981). The resulting
manifestations of soft-tissue injury may be due to
enzymatic reduction of the drug to free radicals
(Powis & Appel, 1980) which can form cytotoxic
hydroxyl radicals in the presence of molecular
oxygen (Fridovich, 1976). These free and hydroxyl
radicals may be susceptible to scavenging by alpha
tocopherol and dimethyl sulphoxide respectively
(Tappel, 1962; Cederbaum et al., 1977). DMSO also
facilitates skin penetration (Kligman, 1965) and
may disperse Adriamycin from within the skin.
Considerations such as these led Svingen et al.
(1981) to investigate the roles of DMSO and alpha
tocopherol in the secondary prevention of
ulceration following i.d. injection of Adriamycin in
rats. Their studies demonstrated that the topical
application of 10% alpha tocopherol succinate in
DMSO at the injection site reduced the mean ulcer
diameter.
In our experiments using a guinea pig model, the
doses of Adriamycin used were critical. By the i.d.
route, 0.01 mg was the minumum amount of the
drug which evoked consistent early lesions; a figure
identical to that obtained by Rudolph et al. (1979).
For animals weighing -250g, a s.c. dose of 2mg
was a satisfactory compromise between early fatal
toxicity and lack of local injury. When the drug
was given by the i.d. route we confirmed the value
of DMSO plus alpha tocopherol succinate in
reducing soft tissue injury. Furthermore, this
beneficial effect was more evident with the higher
concentration of Vitamin E (50%), although it was
progressively less with increasing doses of
Adriamycin.
As a parallel to clinical circumstances, s.c.
injection is a more accurate reflection of
inadvertent extravasation since Adriamycin is
administered customarily into an established i.v.
infusion. Our data on the efficacy of DMSO in
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preventing soft-tissue injury in most animals
following s.c. injection of Adriamycin are thus
clinically valid. There was no merit in applying
DMSO at a site distant from that at which
Adriamycin was injected, as has been suggested by
others (Desai et al., 1981). In any event this
manoeuvre has no relevance to clinical practice.
DMSO is virtually non-toxic in humans (Rubin,
1975), as is alpha tocopherol in less than mega-
doses (Ayres et al., 1979). Although pre-treatment
with systemic Vitamin E may potentiate
Adriamycin-induced myelosuppression in mice
(Alberts et al., 1978), it is unlikely that this will be
a factor in the topical use of small amounts during
the short-term for the prevention of drug-induced
skin necrosis. Therefore we recommend that a
solution of 50% alpha tocopherol succinate in
DMSO be readily available at all times in locations
in which patients are receiving i.v. cytotoxic chemo-
therapy, especially with Adriamycin, so that it may
be applied promptly to any site of suspected
extravasation with a view to preventing or at least
diminishing the consequent soft tissue injury.
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